Intravascular large B-cell lymphoma: Remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy

Barbara Horváth, Judit Demeter, Nóra Eros, Judit Hársing, Judit Csomor, András Matolcsy, Gyula Bottlik, Gabriella Gyori, Márta Marschalkó, Sarolta Kárpáti

Research output: Article

5 Citations (Scopus)

Abstract

Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system. Most cases are of B-cell origin; T-cell phenotype is extremely rare. Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms. The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab. We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.

Original languageEnglish
Pages (from-to)885-888
Number of pages4
JournalJournal of the American Academy of Dermatology
Volume61
Issue number5
DOIs
Publication statusPublished - nov. 1 2009

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Intravascular large B-cell lymphoma: Remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy'. Together they form a unique fingerprint.

  • Cite this